908 Devices and CPI Improve mAbs Cell Culture Outcomes Using At-line Media Analysis
October 12 2022 - 5:00PM
Business Wire
REBEL mass spec device used to reduce toxic
metabolite accumulation while increasing cell viability and titer
by up to 40%
908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld
and desktop devices for chemical and biomolecular analysis,
announced that its collaboration with CPI is demonstrating the
value of at-line cell culture media analysis to inform feeding
strategies for improved cell growth in bioprocessing applications.
Using data from 908 Devices’ REBEL™ desktop device, CPI process
engineers optimized nutrients of a monoclonal antibody-expressing
cell line to increase titer and control toxic metabolites.
CPI process engineers used the REBEL device to monitor amino
acid depletion across a panel of eight commercial cell culture
media at high and low glucose concentrations in a 14-day fed-batch
process in Ambr® 15 micro-bioreactors. Time course data from the
REBEL provided unique insights into the cell metabolism, in
addition to typical cell culture parameters. In a second run using
the Ambr 15 system, these real-time data sets enabled refinement of
media feeding strategies to correct amino acid depletion, improve
cell viability and reduce toxic metabolite accumulation. Results of
the tailored feeding approach, which used a low feed concentration
and amino acid supplementation, enabled up to a 40% increase in
titer while maintaining low levels of toxic metabolites.
The wealth of data provided by the REBEL along with multivariate
modeling and statistical analysis enables users to make such
informed decisions about their process as well as develop
predictive models for feed control, leading to improved efficiency
and robust product quality.
The REBEL analyzer integrates with the well-known and broadly
used Umetrics® data software suite from Sartorius. Data from the
REBEL can be seamlessly imported into MODDE® for design of
experiments (DoE) and SIMCA® for rapid data visualization and
multivariate trend tracking. CPI used SIMCA and MODDE to perform
multivariate analysis of the REBEL data to expedite the
identification of optimal feeding conditions.
CPI is an independent UK-based innovation organization that
works with companies to develop, prove, scale up, and commercialize
new products and processes. To learn more, view the webinar:
Harness the Power of At-line Spent Media Analysis Using the REBEL
to Optimize a CHO mAb Fed-Batch Process.
About the REBEL analyzer
REBEL is a first-of-its-kind fresh and spent media analyzer that
enables biopharma researchers to accelerate process development
cycles and maximize bioreactor utilization by running media
analysis at-line. Key benefits include:
- Efficiency – minimal sample preparation and tiny volume
requirements
- Real-time data tracking – quantitate over 30 key media
nutrients in <10 minutes
- Small and simple – versatile design valued by users
across many applications
For more information, visit www.908devices.com.
Ambr, Umetrics, MODDE and SIMCA are registered trademarks of
Sartorius AG. REBEL is a trademark of 908 Devices Inc.
About 908 Devices
908 Devices Inc. (Nasdaq: MASS) is democratizing laboratory mass
spectrometry with its simple handheld and desktop devices,
addressing critical-to-life applications. The Company’s devices are
used at the point-of-need to interrogate unknown and invisible
materials and provide quick, actionable answers to directly address
some of the most critical problems in life sciences research,
bioprocessing, pharma / biopharma, forensics and adjacent markets.
The Company is headquartered in the heart of Boston, where it
designs and manufactures innovative products that bring together
the power of mass spectrometry, microfluidic separations, software
automation and machine learning.
Forward Looking Statements
This press release includes “forward looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements other than statements of historical facts are
forward-looking statements, including, without limitation,
statements regarding the expected uses and capabilities of the
Company’s products. Words such as “may,” “will,” “expect,” “plan,”
“anticipate,” “estimate,” “intend” and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on
management’s current expectations and involve known and unknown
risks, uncertainties and assumptions which may cause actual results
to differ materially from any results expressed or implied by any
forward-looking statement, including the risks outlined under “Risk
Factors” and elsewhere in the Company’s filings with the Securities
and Exchange Commission which are available on the SEC's website at
www.sec.gov. Additional information will be made available in the
Company’s annual and quarterly reports and other filings that it
makes from time to time with the SEC. Although the Company believes
that the expectations reflected in its forward-looking statements
are reasonable, it cannot guarantee future results. The Company has
no obligation, and does not undertake any obligation, to update or
revise any forward-looking statement made in this press release to
reflect changes since the date of this press release, except as may
be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221012006003/en/
Media Barbara Russo brusso@908devices.com
Investor Carrie Mendivil IR@908devices.com
908 Devices (NASDAQ:MASS)
Historical Stock Chart
From Jul 2024 to Jul 2024
908 Devices (NASDAQ:MASS)
Historical Stock Chart
From Jul 2023 to Jul 2024